A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

NCT04150575 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: HLX10+Albumin-Bound Paclitaxel

Sponsor

Shanghai Henlius Biotech